Serum insulin-like growth factor-binding protein-2 levels and metabolic and cardiovascular risk factors in young adults and children born small for gestational age

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 2, 2010, Pages 864-871

  De Kort, Sandra W K ^a   Van Doorn, Jaap ^b   Van De Sande, Ad G M ^b   Leunissen, Ralph W J ^a   Hokken Koelega, Anita C S ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; LIPID; SOMATOMEDIN BINDING PROTEIN 2; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CARDIOVASCULAR RISK; CHILD; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE HOMEOSTASIS; HORMONE RESPONSE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT STATURE; SMALL FOR DATE INFANT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 76149089072     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1508     Document Type: Article

References (42)

1. Clemmons DR, Snyder DK, Busby Jr WH 1991 Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 73:727-733
2. Bereket A, Lang CH, Blethen SL, Wilson TA 1995 Insulin-like growth factor-binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young. J Clin Endocrinol Metab 80:3647-3652
3. Wheatcroft SB, Kearney MT 2009 IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 20:153-162
4. Hunt KJ, Lukanova A, Rinaldi S, Lundin E, Norat T, Palmqvist R, Stattin P, Riboli E, Hallmans G, Kaaks R 2006 A potential inverse association between insulin-like growth factor I and hypertension in a cross-sectional study. Ann Epidemiol 16:563-571
5. van Haeften TW, Zonderland ML, Sabelis LW, van Doorn J 2007 IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance: response to Maddux et al. Diabetes Care 30:e53; author reply e54
6. van den Beld AW, Blum WF, Pols HA, Grobbee DE, Lamberts SW 2003 Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. Eur J Endocrinol 148: 627-634
7. Krajcik RA, Borofsky ND, Massardo S, Orentreich N 2002 Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11:1566-1573
8. Martin RM, Holly JM, Davey Smith G, Gunnell D 2006 Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr Cohort. J Clin Endocrinol Metab 91:3287-3295
9. Hoeflich A, Wu M, Mohan S, Föll J, Wanke R, Froehlich T, Arnold GJ, Lahm H, Kolb HJ, Wolf E 1999 Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 140:5488-5496
10. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M, Williams SC, Cawthorn WP, Medina-Gomez G, Vidal-Puig A, Sethi JK, Crossey PA 2007 IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 56:285-294
11. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ 2008 Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 149:2051-2061
12. Eriksson JG, Forsén T, Tuomilehto J, Osmond C, Barker DJ 2001 Early growth and coronary heart disease in later life: longitudinal study. BMJ 322:949-953
13. Eriksson JG, Osmond C, Kajantie E, Forsén TJ, Barker DJ 2006 Patterns of growth among childrenwholater develop type 2 diabetes or its risk factors. Diabetologia 49:2853-2858
14. Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, Biswas SK, Ramji S, Prabhakaran D, Reddy KS 2004 Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 350:865-875
15. Giudice LC, de Zegher F, Gargosky SE, Dsupin BA, de las Fuentes L, Crystal RA, Hintz RL, Rosenfeld RG 1995 Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 80:1548-1555
16. Osorio M, Torres J, Moya F, Pezzullo J, Salafia C, Baxter R, Schwander J, Fant M 1996 Insulin-like growth factors (IGFs) and IGF binding proteins-1, -2, and -3 in newborn serum: relationships to fetoplacental growth at term. Early Hum Dev 46:15-26
17. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, Wollmann HA 2000 Significance of basal IGF-I, IGFBP-3 and IGFBP-2 measurements in the diagnostics of short stature in children. Horm Res 54:60-68
18. Usher R, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 74:901-910
19. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM 2000 Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 47:316-323
20. Leunissen RW, Oosterbeek P, Hol LK, Hellingman AA, Stijnen T, Hokken-Koelega AC 2008 Fat mass accumulation during childhood determines insulin sensitivity in early adulthood. J Clin Endocrinol Metab 93:445-451
21. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 1999 Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 84:3064-3070
22. Rosner B, Prineas RJ, Loggie JM, Daniels SR 1993 Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 123:871-886
23. Guo Y, Franks PW, Brookshire T, Antonio Tataranni P 2004 The intra- and inter-instrument reliability of DXA based on ex vivo soft tissue measurements. Obes Res 12:1925-1929
24. Boot AM, Bouquet J, de Ridder MA, Krenning EP, de Muinck Keizer-Schrama SM 1997 Determinants of body composition measured by dual-energy x-ray absorptiometry in Dutch children and adolescents. Am J Clin Nutr 66:232-238
25. Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM 1997 Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab 82:57-62
26. Willemsen RH, Arends NJ, Bakker-van Waarde WM, Jansen M, van Mil EG, Mulder J, Odink RJ, Reeser M, Rongen-Westerlaken C, Stokvis-Brantsma WH, Waelkens JJ, Hokken-Koelega AC 2007 Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial. Clin Endocrinol (Oxf) 67:485-492
27. Cutfield WS, Bergman RN, Menon RK, Sperling MA 1990 The modified minimal model: application to measurement of insulin sensitivity in children. J Clin Endocrinol Metab 70:1644-1650
28. van Dijk M, Bannink EM, van Pareren YK, Mulder PG, Hokken-Koelega AC 2007 Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls. J Clin Endocrinol Metab 92:160-165
29. Willemsen RH, de Kort SW, van der Kaay DC, Hokken-Koelega AC 2008 Independent effects of prematurity on metabolic and cardiovascular risk factors in short small-for-gestational-age children. J Clin Endocrinol Metab 93:452-458
30. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN 2003 MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003-1015
31. de Boer L, Hoogerbrugge CM, van Doorn J, van Buul-Offers SC, Karperien M, Wit JM 2004 Plasma insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), acid-labile subunit (ALS) and IGFBP-3 proteolysis in individuals with clinical characteristics of Sotos syndrome. J Pediatr Endocrinol Metab 17:615-627
32. Van Doorn J, Ringeling AM, Shmueli SS, Kuijpers MC, Hokken-Koelega AC, van Buul-Offers SC, Jansen M 1999 Circulating levels of human insulin-like growth factor binding protein-6 (IGFBP-6) in health and disease as determined by radioimmunoassay. Clin Endocrinol (Oxf) 50:601-609
33. van der Kaay D, Deal C, de Kort S, Willemsen R, Leunissen R, Ester W, Paquette J, van Doorn J, Hokken-Koelega A 2009 Insulin-like growth factor-binding protein-1: serum levels, promoter polymorphism, and associations with components of the metabolic syndrome in short subjects born small for gestational age. J Clin Endocrinol Metab 94:1386-1392
34. Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM 1998 Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 50:166-176
35. Levy JC, Matthews DR, Hermans MP 1998 Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192
36. van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 2003 Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born small for gestational age. J Clin Endocrinol Metab 88:347-353
37. Gunnell D, Oliver SE, Donovan JL, Peters TJ, Gillatt D, Persad R, Hamdy FC, Neal DE, Holly JM 2004 Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab 89:213-218
38. Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM 2006 Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 114:371-376
39. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E 2001 Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 61:8601-8610
40. Ballerini MG, Ropelato MG, Domené HM, Pennisi P, Heinrich JJ, Jasper HG 2004 Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis. J Pediatr Endocrinol Metab 17:749-757
41. Argente J, Caballo N, Barrios V, Pozo J, Muñoz MT, Chowen JA, Hernández M 1997 Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: effect of short- and long-term weight reduction. J Clin Endocrinol Metab 82:2076-2083
42. Radetti G, Bozzola M, Pasquino B, Paganini C, Aglialoro A, Livieri C, Barreca A 1998 Growth hormone bioactivity, insulin-like growth factors (IGFs), and IGF binding proteins in obese children. Metabolism 47:1490-1493